Should therapeutic drug monitoring of the unbound fraction...

Cancer Chemotherapy and Pharmacology 2013 / 02 Vol. 71; Iss. 2

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metaboliteN-desmethyl-imatinib be developed?

Peggy Gandia, Cécile Arellano, Thierry Lafont…
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
71
Language:
english
DOI:
10.1007/s00280-012-2035-3
Date:
February, 2013
File:
PDF, 411 KB
english, 2013
Conversion to is in progress
Conversion to is failed